Tom Thornley

Appearances

PHARMACODYNAMIC DEMONSTRATION OF IMMUNOLOGICAL TOLERANCE INDUCED BY KAN-101, A NOVEL LIVER-TARGETED THERAPY FOR CELIAC DISEASE, PERSISTS FOLLOWING DRUG CLEARANCE
Date
May 9, 2023
INTRODUCTION Interleukin-15 (IL-15) is an important cytokine involved in tissue homeostasis and inflammation, and a potent regulator of innate and adaptive immune responses…
Presenter
Joseph Murray
Speakers
Dina Wassaf
Stephanie Morgan
Stephan Kontos
Kaela Goldstein
Tom Thornley
Kristie Grebe
ASSESSMENT OF KAN-101 IN CED AND IMMUNE TOLERANCE (ACED-IT) STUDY, PH1B DATA WITH HIGHER DOSE LEVELS OF KAN-101, A NOVEL IMMUNE TOLERANCE THERAPY FOR CELIAC DISEASE
Date
May 19, 2024
Background: Celiac disease (CeD) is a chronic inflammatory disorder triggered and maintained by ingestion of gluten. The only treatment is a gluten-free diet as no pharmaceutical treatment is available…
Speakers
Jack Tseng
Stephanie Morgan
Dina Wassaf
Jyoti Ramakrishna
Ashwin Karanam
Mohamed Hassanein
William Treem
Tom Thornley
Presenter
Kristie Grebe